Evotec SE has appointed Dr. Ashiq H. Khan as EVP Global Head, Chief Commercial Officer.

Khan brings over 15 years of international leadership experience in biotech, CRO and AI-driven platform businesses, with a track record of managing diverse transcontinental teams and closing more than $7 billion in high-value standalone, integrated, and collaboration agreements across the U.S., EU and APAC markets. In his role, Khan will spearhead the build-out of a globally integrated, fit-for-purpose commercial organization fully aligned with Evotec’s scientific leadership and platform capabilities to deliver enhanced customer value and drive more robust, sustainable growth.

Dr. Christian Wojczewski, CEO of Evotec, said: “Ashiq has demonstrated tremendous success driving growth in innovative areas like robotics, artificial intelligence and cutting-edge drug discovery platforms. His expertise is essential for executing the next stage of Evotec’s transformation as a responsive drug discovery and development engine built around high-value services and capabilities. We are excited to have someone with his experience in recognizing and creating new opportunities at the helm of our commercial team.”

Experience

Khan most recently served as Chief Business Officer at Iktos. Prior to that, he held leadership roles at Proteros and Schrödinger. He holds a Ph.D. in Neurobiology from the University of Cologne and business degrees from the Wharton Business School and INSEAD.

“As new technologies continue to transform the field, I am fully committed to working with Evotec’s exceptional scientific, operational, and business leaders to further strengthen our capabilities and drive the next generation of breakthrough therapies,” Khan remarked.